Helios Corp. celebrates receiving Fi Editor's Choice Award for best science

Helios Corp. celebrates receiving Fi Editor's Choice Award for best science

Helios CORP, in partnership with Sunbio, received the Functional Ingredients Editor's Choice Award for Best Science at the Engredea trade show, co-located with Expo West. Helios CORP takes cultural remedies and translates these into commercial ingredients with human clinical studies.


Helios CORP, in partnership with Sunbio, received the Functional Ingredients Editor's Choice Award for Best Science at the Engredea trade show, co-located with Expo West. Helios CORP takes cultural remedies and translates these into commercial ingredients with human clinical studies. CEO of Helios CORP, Michael Jeffers, indicated that the honor in receiving this award goes beyond words. He stated, "we have worked diligently to transform product categories with our performance based clinical science and we are grateful that the event team acknowledged our efforts within the nutritional industry."
 
At Engredea, Helios presented multiple, science based ingredients. The highlight product was EstroG-100 for menopause and feminine discomfort. EstroG-100 maintains a human Phase I, and a USA based Phase II human clinical study, 2 anti cancer studies, 2 liver safety studies, 2 non-estrogenic studies, 5 toxicity studies, a no objection letter from FDA, and a Health Canada Registration# with 10 end point claims to go with it. EstroG-100 continues to test for, and avalidate additional benefits for women such as improvements in skin tone and speed of action (within 7 days). A game changer in the female category with extensive safety, and multiple end point claims.
 
Other key products at the booth with Phase I and Phase II human clinical studies included Diabetinol for Glucose Intolerance/ Blood Sugar Management and the only such natural ingredient in this category with two USA based, registered human clinical studies. Also presented; the only natural ingredient to increase bone density without any special supplementation: NC-518. In the USA based Phase II clinical NC-518 increased bone density 2.0% over 4 months as compared to placebo which was 1200mgs of Calcium Carbonate with 800IU's of Vitamin D3.
 
When interviewed at the show by Functional Ingredients editors, CEO of Helios CORP, Michael Jeffers, indicated "Helios CORP. remains dedicated to the process of providing end use manufacturers with the ability to make strong, structure function claims with Helios branded ingredients, which are backed by performance based and independently validated human clinical studies. All with full toxicity data". He also mentioned that  "Helios focuses on ingredient science that will transform specific categories". The Top Science Company Award is a direct confirmation of what Helios is accomplishing in the Nutritional sector. Helios Corp and Sunbio remain committed to validating the integrity of our industry and setting an example of excellence that all end use manufacturers and marketers should expect.
 
About Helios and Sunbio: Helios Corp. and Sunbio are a privately owned and global companies that develop new ideas, science, and cultural remedies that can be translated into commercial applications for the benefit of manufacturers and consumers. Claims and representations are based on the information, data, clinical studies,  and remedies as provided by our science and manufacturing partners.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish